On Thursday, Novavax Inc ( NVAX ) reported fourth-quarter 2024 sales of $88.31 million, compared to $291 million a year, beating the consensus of $84.35 million. The decrease was due to lower product sales under APA agreements.

The COVID-19 vaccine maker reported an earning loss of 51 cents per share, down from $1.44 a year ago, in line with the Wall Street Estimate.

Also Read: Wegovy Maker Novo Nordisk To Buy Novavax’s Czech Republic Manufacturing Facility For $200 Million

“In 2024, we unveiled our new corporate growth strategy, shifting our focus from commercializing our COVID-19 vaccine to maximizing the value of our cutting-edge technology platform through pipeline expansion and partnerships for our development-stage vaccine candidates and our Matrix-M adjuvant,” said John C. Jacobs, President and Chief Executive Officer, Novavax ( NVAX ). “As we look to 2025 and beyond, we believe we are well positioned to potentially create significant value for all stakeholders.”

Nuvaxovid sales reached $49.8 million, down from $251.5 million a year ago. The company ended 2024 with over $1 billion in cash and accounts receivables.

Novavax ( NVAX ) has transitioned the lead commercial responsibility of Nuvaxovid to Sanofi SA ( SNY ) for select markets beginning with the 2025-2026 vaccination season.

Since Novavax ( NVAX ) is reliant on Sanofi’s sales forecasts for certain revenue components, these will not be included in the 2025 Revenue Framework at this time.

Novavax ( NVAX ) expects to achieve adjusted licensing, royalties, and other revenue of between $300 million and $350 million in 2025. Novavax ( NVAX ) is eligible to receive royalties in the high teens to low twenties percent on Sanofi ( SNY ) sales.

Novavax Stock Prediction For 2025

Equity research can be a valuable source of information for learning about a company's fundamentals. Analysts create financial models based on the fundamentals and expected future earnings of a company to arrive at a price target and recommendation for the stock.

Shares of Novavax ( NVAX ) have an average 1-year price target of $19.0, representing an expected upside of 141.41%.

Because of differences in assumptions, analysts can arrive at very different price targets and recommendations. No analysts have bearish recommendations on Novavax ( NVAX ), while 1 analysts have bullish ratings. The street high price target from HC Wainwright & Co. is $19.0, while the street low from HC Wainwright & Co. is $19.0.

Price Action: NVAX stock is up 10.4% at $8.08 at the last check Thursday.

Read Next:

Why Is Ad Giant WPP Stock Falling Today?